Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 82 of 6351
-
Can a Bladder-Directed biologic outsmart Treatment-Resistant bladder cancer?
Disease control Recruiting nowThis is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.
Phase 2 • Sponsor: ImmVira Pharma Co. Ltd • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Promising new combo therapy for infant leukemia shows potential
Disease control Recruiting nowThis phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without a KMT2A gene rearrangement (KMT2A-germli…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 01:00 UTC
-
New vaccine trial aims to protect kids from mosquito virus
Vaccine Recruiting nowThe goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to \<12 years of age.
Phase 3 • Sponsor: Bavarian Nordic • Aim: Vaccine
Last updated Jun 27, 2026 12:00 UTC
-
New Cholesterol-Lowering pill could prevent heart attacks
Disease control Recruiting nowThe purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The eff…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for kids with severe epilepsy: drug trial targets seizures
Disease control Recruiting nowThe purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
Phase 3 • Sponsor: Stoke Therapeutics, Inc • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New combo shot aims for major weight loss in obesity trial
Disease control OngoingThis study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants …
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for HER2+ breast cancer: phase 3 trial compares next-gen drug to standard therapy
Disease control Recruiting nowThis trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in the adjuvant treatment of HER2-positive breast cancer with residual invasive cancer after neoadjuvant therapy.
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hep c combo aims to match top therapy in phase 3 showdown
Disease control OngoingThe purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Phase 3 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can a Triple-Drug combo outsmart stubborn stomach cancer?
Disease control Recruiting nowThis is a Single-arm, Open-label, Phase 1b/2 Study of IBI343 Combined with Sintilimab Plus Chemotherapy in Previously Untreated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1/2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Could an ancient remedy cut early deaths in leukemia?
Disease control Recruiting nowStudy Title: Multicenter, Randomized Controlled Clinical Study on Early Application of Realgar-Indigo Naturalis Formula (RIF) for Treatment of Acute Promyelocytic Leukemia (APL) Sponsor: Xi'an Jiaotong University First Affiliated Hospital Principal Investigator: Wang Huaiyu …
Phase 3 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could the type of IV fluid change brain injury recovery?
Disease control Recruiting nowThe goal of this clinical trial is to determine which crystalloid (saline or balanced) should be used in the critical management of Traumatic Brain Injury (TBI) in moderate or severe TBI patients. This trial will determine whether the use of saline or balanced crystalloids is ass…
Phase 3 • Sponsor: University of Louisville • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a psychedelic compound help veterans and first responders with PTSD and alcohol use disorder?
Disease control OngoingThis study is a phase 2 single-site, double-blind, placebo-controlled, randomized clinical trial with an open-label extension phase to examine the safety of psilocybin (25 mg) combined with psychological support (Psi-PS) for treatment of approximately 40 military veterans and fir…
Phase 2 • Sponsor: Nathan Brashares Sackett • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Promising new combo therapy targets Hard-to-Treat gut tumors
Disease control Recruiting nowThe purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo aims to boost immune attack on HPV-Driven head and neck cancer
Disease control Stopped earlyThis is a global, multi-center, Phase 3 study that is randomized 1:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs. pembrolizumab monotherapy as first-line treatment in patients with unresectable recurrent or metastatic …
Phase 3 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Promising new combo aims to beat aggressive leukemia
Disease control Recruiting nowThis pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-Cell acute lymphoblastic leukemia (…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 01:00 UTC
-
New malaria vaccine schedule trial aims to protect infants
Vaccine Recruiting nowThe aim of this study is to identify an optimal infant vaccine schedule for a malaria vaccine which is better aligned with the timing of other vaccine interventions.
Phase 2 • Sponsor: PATH • Aim: Vaccine
Last updated Jun 27, 2026 12:33 UTC
-
Mpox vaccine trial for infants: could a Half-Dose protect just as well?
Vaccine OngoingThis Phase 3 double-blinded, randomized study aims to evaluate the safety and immunogenicity of the two-dose MVA-BN mpox vaccine regimen, administered subcutaneously, in infants and children aged 4 to 24 months in the Democratic Republic of the Congo (DRC), a population at high r…
Phase 3 • Sponsor: Jean-Pierre Van geertruyden • Aim: Vaccine
Last updated Jun 27, 2026 12:25 UTC
-
New mRNA vaccine combo aims to halt advanced melanoma
Disease control Recruiting nowResearchers want to learn if intismeran autogene with pembrolizumab can stop advanced melanoma from growing or spreading. Melanoma is a type of skin cancer. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. A standard (or usual) t…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can a pill keep lung cancer from returning after surgery?
Disease control Recruiting nowThis is a Phase 3, global, double-blind, randomized, controlled multicenter clinical study to assess the efficacy and safety of adjuvant treatment with firmonertinib versus placebo in participants with Stage IB-IIIB NSCLC with uncommon EGFR mutations (exon 20 insertions, PACC and…
Phase 3 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New family therapy aims to stop teen suicide attempts
Disease control Recruiting nowSuicide is the leading cause of death amongst 10-18-year-olds in Sweden. Suicide attempts are the strongest predictor of subsequent death by suicide, often lead to inpatient care, and are associated with substantial societal costs, making suicide attempts a critical target in psy…
Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC